Hybrid cis-stilbene molecules: Novel anticancer agents

34Citations
Citations of this article
58Readers
Mendeley users who have this article in their library.

Abstract

The growing interest in anticancer hybrids in the last few years has resulted in a great number of reports on hybrid design, synthesis and bioevaluation. Many novel multi-target-directed drug candidates were synthesized, and their biological activities were evaluated. For the design of anticancer hybrid compounds, the molecules of stilbenes, aromatic quinones, and heterocycles (benzimidazole, imidazole, pyrimidine, pyridine, pyrazole, quinoline, quinazoline) were applied. A distinct group of hybrids comprises the molecules built with natural compounds: Resveratrol, curcumin, coumarin, and oleanolic acid. In this review, we present the studies on bioactive hybrid molecules of a well-known tubulin polymerization inhibitor, combretastatin A-4 and its analogs with other pharmacologically active entities. The mechanism of anticancer activity of selected hybrids is discussed considering the structure-activity relationship.

Author supplied keywords

Cite

CITATION STYLE

APA

Piekuś-Słomka, N., Mikstacka, R., Ronowicz, J., & Sobiak, S. (2019, March 2). Hybrid cis-stilbene molecules: Novel anticancer agents. International Journal of Molecular Sciences. MDPI AG. https://doi.org/10.3390/ijms20061300

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free